Cancer immumotherapy

Avoiding the road to perdition

Maurizio Chiriva-Internati, Fabio Grizzi, Robert K. Bright, W. Martin Kast

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The hypothesis that human cancers express antigens that can be specifically targeted by cell mediated immunity has become a scientifically justifiable rationale for the design and clinical testing of novel tumor-associated antigens (TAA). Although a number of TAA have been recognized and it has been suggested that they could be useful in the immunological treatment of cancer, the complexity of human beings leads us to reflect on the need to establish new criteria for validating their real applicability. Herein, we show a system level-based approach that includes morphological and molecular techniques, which is specifically required to improve the capacity to produce desired results and to allow cancer immunotherapy to re-emerge from the mist in which it is currently shrouded.

Original languageEnglish
Article number26
JournalJournal of Translational Medicine
Volume2
DOIs
Publication statusPublished - Jul 29 2004

Fingerprint

Neoplasm Antigens
Antigens
Tumors
Neoplasms
Fog
Cellular Immunity
Immunotherapy
Testing
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Cancer immumotherapy : Avoiding the road to perdition. / Chiriva-Internati, Maurizio; Grizzi, Fabio; Bright, Robert K.; Kast, W. Martin.

In: Journal of Translational Medicine, Vol. 2, 26, 29.07.2004.

Research output: Contribution to journalArticle

Chiriva-Internati, Maurizio ; Grizzi, Fabio ; Bright, Robert K. ; Kast, W. Martin. / Cancer immumotherapy : Avoiding the road to perdition. In: Journal of Translational Medicine. 2004 ; Vol. 2.
@article{5f685157308b4adeacc8efcb57b0e4b1,
title = "Cancer immumotherapy: Avoiding the road to perdition",
abstract = "The hypothesis that human cancers express antigens that can be specifically targeted by cell mediated immunity has become a scientifically justifiable rationale for the design and clinical testing of novel tumor-associated antigens (TAA). Although a number of TAA have been recognized and it has been suggested that they could be useful in the immunological treatment of cancer, the complexity of human beings leads us to reflect on the need to establish new criteria for validating their real applicability. Herein, we show a system level-based approach that includes morphological and molecular techniques, which is specifically required to improve the capacity to produce desired results and to allow cancer immunotherapy to re-emerge from the mist in which it is currently shrouded.",
author = "Maurizio Chiriva-Internati and Fabio Grizzi and Bright, {Robert K.} and Kast, {W. Martin}",
year = "2004",
month = "7",
day = "29",
doi = "10.1186/1479-5876-2-26",
language = "English",
volume = "2",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Cancer immumotherapy

T2 - Avoiding the road to perdition

AU - Chiriva-Internati, Maurizio

AU - Grizzi, Fabio

AU - Bright, Robert K.

AU - Kast, W. Martin

PY - 2004/7/29

Y1 - 2004/7/29

N2 - The hypothesis that human cancers express antigens that can be specifically targeted by cell mediated immunity has become a scientifically justifiable rationale for the design and clinical testing of novel tumor-associated antigens (TAA). Although a number of TAA have been recognized and it has been suggested that they could be useful in the immunological treatment of cancer, the complexity of human beings leads us to reflect on the need to establish new criteria for validating their real applicability. Herein, we show a system level-based approach that includes morphological and molecular techniques, which is specifically required to improve the capacity to produce desired results and to allow cancer immunotherapy to re-emerge from the mist in which it is currently shrouded.

AB - The hypothesis that human cancers express antigens that can be specifically targeted by cell mediated immunity has become a scientifically justifiable rationale for the design and clinical testing of novel tumor-associated antigens (TAA). Although a number of TAA have been recognized and it has been suggested that they could be useful in the immunological treatment of cancer, the complexity of human beings leads us to reflect on the need to establish new criteria for validating their real applicability. Herein, we show a system level-based approach that includes morphological and molecular techniques, which is specifically required to improve the capacity to produce desired results and to allow cancer immunotherapy to re-emerge from the mist in which it is currently shrouded.

UR - http://www.scopus.com/inward/record.url?scp=4344564149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344564149&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-2-26

DO - 10.1186/1479-5876-2-26

M3 - Article

VL - 2

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

M1 - 26

ER -